Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation

Sensitive, scalable and affordable measurable residual disease (MRD) assays are needed to guide treatment decisions in acute myeloid leukemia (AML), particularly around allogeneic hematopoietic stem cell transplantation (allo-SCT). Next-generation sequencing (NGS)-based MRD assays offer broad appli...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Simon M. Krauß, Tara Holloway, Anne Weigert, Lara Bischof, Donata Backhaus, Dominic Brauer, Jule Ussmann, Georg-Nikolaus Franke, Vladan Vučinić, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch, Klaus H. Metzeler
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Ferrata Storti Foundation 2026-05-01
סדרה:	Haematologica
גישה מקוונת:	https://haematologica.org/article/view/14203
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!